Streptococcus pneumoniae capsular polysaccharide (serotype-specific)

The listed target is not a single molecule or receptor but rather a group of **capsular polysaccharides** that define the major clinically relevant serotypes of *Streptococcus pneumoniae*. These surface carbohydrates are the primary antigens used in pneumococcal vaccines such as PCV13 and PPSV23. Each serotype’s unique capsule structure enables immune evasion and contributes to pathogenicity. Vaccines containing these purified or conjugated capsular antigens induce protective antibody responses that reduce the risk of invasive pneumococcal diseases like pneumonia and meningitis. The term as given is not a canonical molecular target but refers collectively to multiple bacterial surface antigens used for immunization purposes[1][2][3]. **Note:** This entry is considered "incorrect" as a therapeutic target because it does not refer to a single molecule/receptor/protein but rather an aggregate list of bacterial antigenic types used for vaccine formulation. The correct structured information would be at the level of each individual "Streptococcus pneumoniae capsular polysaccharide" by serotype. “More than 90 serotypes... have been identified based on varying polysaccharides found in the bacterial cell wall... Purified polysaccharide vaccines contain these serotypes... Antibody responses develop following immunization with purified [or conjugated] vaccines.”[1][2]

Other names

Pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23FS. pneumoniae serotypes (vaccine types)

Induction of protective antibodies against specific capsular polysaccharides to prevent invasive pneumococcal disease[1][2]